Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)

NCT03377556 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT03377556
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03377556 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Completed
Start date
March 3, 2017
Completion date
April 16, 2021
Enrollment
51 (actual)
Sites
1,157

Conditions

As the registry lists them; a condition with its own page is linked.

atm gene mutation, atr gene mutation, bard1 gene mutation, brca1 gene mutation, brca2 gene mutation, brip1 gene mutation, chek1 gene mutation, chek2 gene mutation, fanca gene mutation, fancc gene mutation, fancd2 gene mutation, fancf gene mutation, fancm gene mutation, nbn gene mutation, palb2 gene mutation, rad51 gene mutation, rad51b gene mutation, rad54l gene mutation, recurrent squamous cell lung carcinoma, rpa1 gene mutation, stage iv squamous cell lung carcinoma ajcc v7